Episode Details
Back to Episodes
July 01, 2026| Tregzi Approved — Orca Bio Opens a New Lane in Cell Therapy
Published 3 weeks, 1 day ago
Description
FDA approves Orca Bio's Tregzi — the first precision-engineered cell therapy for allogeneic transplant, sparking IPO speculation. Plus BridgeBio secures $1B from Sixth Street and KKR at a 100%+ conversion premium, Ipsen's $2.55B deal spree continues with Memo Therapeutics,Merck scraps Alzheimer's drug MK-1167 as AlzeCure lands a $2.2B QuantumCell partnership, and FDA warns Sanofi's Genzyme over Altuviiio production.
Visit us at www.thepharmacloseout.com
pharma, biotech, FDA, clinical trials, drug approvals, OrcaBio, Tregzi, BridgeBio, Ipsen, Merck, Alzheimer's, cell therapy